RAV 12

Drug Profile

RAV 12

Alternative Names: ANTI-RAAG12-MAB; RAV12

Latest Information Update: 14 May 2012

Price : $50

At a glance

  • Originator Raven biotechnologies
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cell membrane modulators; Complement activation stimulants; Immunostimulants; Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Adenocarcinoma; Pancreatic cancer

Most Recent Events

  • 01 May 2012 Discontinued - Phase-I/II for Adenocarcinoma in USA (IV)
  • 01 May 2012 Discontinued - Phase-II for Pancreatic cancer in USA (IV)
  • 17 Jul 2008 Raven biotechnologies has been acquired by MacroGenics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top